Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age (Q73318541)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

6

L van Alphen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

E D de Kleijn

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R de Groot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

J Labadie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A B Lafeber

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G van den Dobbelsteen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H van Dijken

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

B Kuipers

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G W van Omme

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Wala

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

R Juttmann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H C Rümke

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

language of work or name

English

0 references

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1456-1466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

Appearance of new strains associated with group B meningococcal disease and their use for rapid vaccine development

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human immunity to the meningococcus. II. Development of natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Immunogenicity of group A and group C meningococcal polysaccharides in human infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Meningococcal vaccines—present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900423-5

7 January 2021

10.1016/S0264-410X(99)00423-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10618543%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference